ClinicalTrials.Veeva

Menu

The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines

H

Huons

Status and phase

Unknown
Phase 3

Conditions

Glabellar Frown Lines

Treatments

Biological: Botox Inj
Biological: Hutox Inj

Study type

Interventional

Funder types

Industry

Identifiers

NCT03440671
HU-014_P3

Details and patient eligibility

About

A Phase Ⅲ Clinical Trial to Compare the Safety and Efficacy of Hutox versus Botox® in Subject with Moderate to Severe Glabellar Lines

Enrollment

260 estimated patients

Sex

All

Ages

20 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Facial Wrinkle Scale (FWS) score > 2 when Subject knits brow extremely

Exclusion criteria

  • Volunteer who has history of any diseases following. (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis etc.)
  • From screening, Subject who get a plastic Surgery including fascioplasty, Prosthesis implantation within 6 Weeks
  • Subject who takes a medication including skeletal muscle relaxants, Aminoglycoside, lincomycin, anticholinergic drug, benzodiazepine, benzamide etc
  • Subject who takes a medication including anticoagulant, antithrombotic drug except low dose aspirin (below 325 mg/day)
  • Any condition that, in the view of the investigator, would interfere with study participation

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

260 participants in 2 patient groups

Hutox Inj
Experimental group
Description:
Hutox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
Treatment:
Biological: Hutox Inj
Botox Inj
Active Comparator group
Description:
Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
Treatment:
Biological: Botox Inj

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems